logo
logo

Surf Bio Announces $16 Million Series Seed Financing

Apr 12, 2022•over 3 years ago

Amount Raised

$16 Million

Round Type

seed

Palo Alto

Description

Surf Bio, Inc., a biopharmaceutical company commercializing a novel drug stabilization platform, today announced a $16 million Series Seed round of funding. The financing was co-led by Breakout Ventures and the Perceptive Xontogeny Venture Fund (“PXV Fund”). The company will use the funds to advance its polymer-based drug delivery platform and accelerate the development of an ultra-rapid insulin for treatment of diabetes.

Company Information

Company

Surf Bio

Location

Palo Alto, California, United States

About

Surf Bio is a preclinical biopharmaceutical company leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. Surf Bio was launched by the founders of Bigfoot Biomedical and Mode AGC to commercialize a breakthrough drug stabilization technology developed in the Appel Lab. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas. For more information about Surf Bio, visit www.surf.bio.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech